A cancer and precancerous screening composition for esophageal cancer, gastric cancer, intestinal cancer, liver cancer and / or pancreatic cancer and its use
Through the Septin9 gene methylation detection kit, the problem of early detection of precancerous lesions and precancerous diseases of the digestive tract is solved, and high sensitivity and specificity screening is achieved, filling the resources and compliance shortcomings of the existing technology. .
Patent Information
- Application Number
- CN202211489558.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-02-14
- Filing Date
- 2019-10-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-10-21
AI Technical Summary
The prior art is difficult to effectively screen precancerous lesions and precancerous diseases of the digestive tract, especially early detection of esophageal, gastric, colorectal, liver and pancreatic cancers. The compliance of imaging and endoscopy is low and the resources are limited, and the lack of high Sensitivity and high specificity detection method.
Develop a kit and method based on Septin9 gene methylation detection. By detecting the methylation degree of Septin9 gene in a specific target region, using primers and probes for PCR amplification, the risk of cancer in the digestive tract and precancerous Early screening of lesions and precancerous diseases.
Improve the detection rate of precancerous lesions and precancerous diseases of the digestive tract, provides a non-invasive, safe and non-invasive auxiliary detection method, which is of great value to people who reject endoscopy or imaging examinations, and significantly improves the Sensitivity and specificity of early screening.
Smart Images

Figure GDA0005059520350000211 
Figure GDA0005059520350000221 
Figure GDA0005059520350000231
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201910999215.1, invention name “A composition for health epigenomics and its use” and application date October 21, 2019. Technical Field
[0002] The present invention relates to the field of biomedicine technology, and in particular to a kit for detecting epigenetic variation, namely Septin9 gene methylation, and a detection method thereof and application thereof in screening for the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases. Background Art
[0003] Esophageal cancer is a malignant tumor originating from the esophageal mucosal epithelium. It is one of the most common clinical malignant tumors. The incidence of esophageal cancer ranks 8th among malignant tumors worldwide. Early esophageal cancer that only involves the mucosal layer and the superficial submucosal layer can usually be cured by minimally invasive endoscopic treatment, which has the same efficacy as surgery and has the advantages of less trauma, less pain, and faster recovery. The 5-year survival rate of patients can exceed 95%. The Outline of the China Cancer Prevention and Control Plan (2004-2010) clearly states that early detection, early diagnosis and early treatment of cancer are the main strategies to reduce mortality and improve survival rates. Endoscopic early treatment based on improving the detection rate and diagnosis rate of early lesions is an effective way to improve the prognosis of esophageal cancer patients, save national medical resources, and reduce the burden on families and society. The "Expert Consensus on Early Esophageal Cancer Screening and Endoscopic Diagnosis and Treatment in China (2014, Beijing)" points out that chronic esophagitis, Barrett's esophagus, esophageal leukoplakia, esophageal diverticulum, achalasia, reflux esophagitis, benign esophageal strictures caused by various reasons, etc. are benign diseases related to esophageal cancer and have a certain rate of canceration, collectively referred to as esophageal precancerous diseases. Therefore, in addition to early detection of esophageal cancer, early detection and intervention of the above precancerous diseases are also required.
[0004] Gastric cancer refers to an epithelial malignant tumor that originates in the stomach. Patients with early gastric cancer often have no specific symptoms. As the disease progresses, symptoms similar to those of gastritis and ulcer disease may appear, mainly including: 1) upper abdominal distension or dull pain, which is more severe after meals; 2) loss of appetite, belching, acid reflux, nausea, vomiting, black stools, etc. In addition to the above symptoms, advanced gastric cancer often presents with: 1) weight loss, anemia, and fatigue; 2) stomach pain. If the pain continues to worsen and radiates to the waist and back, it indicates that the pancreas and celiac plexus may be invaded. Once gastric cancer perforates, severe abdominal pain and gastric perforation symptoms may occur; 3) nausea and vomiting, which are often caused by tumor obstruction or gastric dysfunction. Cardiac cancer may cause progressive dysphagia and reflux symptoms. When pyloric obstruction is caused by gastric antral cancer, vomiting of food may occur; 4) bleeding and black stools. Tumors invade blood vessels and may cause gastrointestinal bleeding. When the amount of bleeding is small, only fecal occult blood is positive. When the amount of bleeding is large, it may manifest as vomiting blood and black stools; 5) other symptoms such as diarrhea (caused by lack of gastric acid and accelerated gastric emptying) and symptoms of metastatic lesions. Late-stage patients may experience severe weight loss, anemia, edema, fever, jaundice, and cachexia. Although the symptoms of gastric cancer are very similar to other gastric diseases, it is generally believed that the development of gastric cancer goes through six stages: superficial gastritis, atrophic gastritis, intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and gastric cancer. Therefore, for the prevention of gastric cancer, early detection and intervention of precancerous diseases (such as atrophic gastritis and intestinal metaplasia) are particularly important. Currently, the commonly used effective detection methods for gastric diseases almost all rely on gastroscopy, but the compliance of gastroscopy is low, and the number of gastroscopy resources and clinical technicians cannot meet the needs, so effective screening methods are still needed.
[0005] Colorectal cancer is a common malignant tumor, with about 900,000 cases worldwide each year. It is one of the most common digestive tract malignancies. Malignant tumors of the large intestine originate from the mucosal epithelium or submucosal mesenchymal tissue. Among them, malignant tumors that occur in the mucosal epithelium of the large intestine under the influence of various carcinogenic factors such as the environment or genetics are collectively referred to as colorectal cancer. The sites of colorectal cancer are the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum. It is a general term for colon cancer and rectal cancer, also known as colorectal cancer. Colorectal cancer is a malignant tumor that seriously threatens human life and health. Epidemiological survey data worldwide show that the incidence of colorectal cancer ranks third among all types of malignant tumors. It is a common digestive tract malignant tumor and ranks second among gastrointestinal tumors. The incidence of colorectal cancer is second only to gastric and esophageal cancer. Early colorectal cancer may have no obvious symptoms. When the disease develops to a certain extent, the following symptoms may appear: changes in bowel habits, changes in stool characteristics (such as thinning, bloody stools, mucous stools, etc.), abdominal pain or abdominal discomfort, abdominal masses, symptoms related to intestinal obstruction, anemia and systemic symptoms (such as weight loss, fatigue, low fever, etc.). The onset of colorectal cancer may be related to the following diseases: ulcerative colitis, colorectal polyposis, colorectal adenomas, Crohn's disease, schistosomiasis, etc., and the patient's relevant medical history should be asked in detail. Therefore, in addition to improving the early diagnosis rate of early colorectal cancer, other intestinal diseases, especially early detection of polyps and adenomas, play an especially important role in the prevention of colorectal cancer. Data show that a colonoscopy can reduce the risk of colorectal cancer by 30% within 17 years. Although colonoscopy can detect polyps, adenomas, and colorectal cancer in the early stage, due to the invasiveness of colonoscopy, the compliance in clinical practice is relatively low. At present, it cannot be widely promoted in clinical practice for the screening of colorectal cancer and precancerous diseases. Therefore, the market urgently needs simple, highly sensitive, and highly compliant test kits for early detection of colorectal precancerous diseases.
[0006] Primary liver cancer is one of the three major causes of cancer death in the world. In 2000, about 548,600 people died of liver cancer. The prognosis of primary liver cancer is very poor, with an average survival time of less than 6 months from diagnosis. Therefore, the mortality rate is similar to the incidence rate. In areas with a high incidence of liver cancer, most HBV infections start in the perinatal period or early childhood. The emergence of safe and effective hepatitis B vaccines and routine vaccination in newborns is expected to significantly reduce the incidence of liver cancer caused by HBV in three or four decades. In recent years, the relationship between hepatitis C virus (HCV) infection and liver cancer has received widespread attention, but there is currently a lack of effective measures to control HCV infection and prevent the occurrence of liver cancer. Screening, early detection, early diagnosis, and early treatment of liver cancer, that is, secondary prevention of liver cancer, is expected to reduce the mortality rate of liver cancer. The "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2017 Edition)" points out that screening of high-risk groups for liver cancer is conducive to early detection, early diagnosis, and early treatment, and is the key to improving the efficacy of liver cancer. In my country, the high-risk groups for liver cancer mainly include those with hepatitis B virus (HBV) and / or hepatitis C virus (HCV) infection, long-term alcoholism, non-alcoholic fatty hepatitis, consumption of food contaminated by aflatoxin, cirrhosis caused by various reasons, and a family history of liver cancer, especially men over the age of 40 are at greater risk. Therefore, if there is a simpler method to detect liver cirrhosis besides B-ultrasound, it will be more helpful for early prevention of liver cancer.
[0007] Pancreatic cancer is a highly malignant digestive tract tumor that is difficult to detect and treat. An important factor leading to the high mortality rate and low cure rate of pancreatic cancer is that the diagnosis rate of early pancreatic cancer is significantly lower than that of other cancers. Since early pancreatic cancer lacks obvious and specific symptoms, most patients are already in the late stage of cancer when diagnosed. At this time, the lesions have mostly metastasized and cannot be treated with curative means. Clinical studies in recent years have shown that there is still a chance to cure pancreatic cancer: since it takes an average of 2-3 years from the formation of pancreatic cancer lesions to the onset of clinical symptoms in patients, this provides an effective window period for the discovery of early pancreatic cancer and the improvement of the diagnosis rate of early pancreatic cancer; making full use of this window period is expected to improve the treatment effect of pancreatic cancer and reduce the mortality rate of pancreatic cancer. High-risk factors for pancreatic cancer include smoking, obesity, alcoholism, chronic pancreatitis, etc., and those who are exposed to naphthylamine and benzene compounds have a significantly increased risk of pancreatic cancer. Diabetes is one of the risk factors for pancreatic cancer, especially for the elderly, low body mass index, and patients with no family history of diabetes. When new-onset type 2 diabetes occurs, attention should be paid to follow-up and be alert to the possibility of pancreatic cancer. At the same time, pancreatic cancer has a genetic susceptibility. About 10% of pancreatic cancer patients have a genetic background. Patients with hereditary pancreatitis, Peutz-Jeghers syndrome, familial malignant melanoma and other hereditary tumor diseases have a significantly increased risk of pancreatic cancer. Therefore, the prevention of pancreatic cancer should also achieve early detection and intervention of the above diseases in the early stage.
[0008] In summary, although imaging and endoscopy are currently one of the effective methods for screening cancer and precancerous lesions and precancerous diseases, they are still not suitable for universal screening due to low compliance and limited domestic resources and professional technicians. Therefore, compared with imaging and endoscopy, detection methods with higher compliance and high sensitivity are effective methods for early prevention and early intervention of precancerous lesions and precancerous diseases of the digestive tract.
[0009] DNA methylation is an important research topic in epigenetics. It plays an important role in maintaining normal cell function, genetic imprinting, embryonic development, and human tumorigenesis. It is one of the new research hotspots. Changes in DNA methylation status are an important factor in causing tumorigenesis. This change includes a decrease in the overall methylation level of the genome and an abnormal increase in the local methylation level of CpG islands, which leads to genomic instability and induces cell carcinogenesis. The essence of DNA methylation is that when abnormal events occur in cells, the expression of DNA methyltransferase increases, causing the hydrogen atom attached to the fifth carbon atom of cytosine in DNA to be replaced by a methyl group (such as Figure 2As shown in Figure 2.2, the conformation of DNA changes, RNA polymerase cannot pass through the methylated DNA region, resulting in the inability to express genes downstream of methylation, and ultimately leading to cell dysfunction and tumors. Studies have found that DNA methylation occurs in the precancerous stage, and as the methylation level continues to increase, the disease continues to develop and eventually evolves into cancer (e.g. Figure 3 shown).
[0010] Variations at the epigenetic level are more frequent than gene mutations, so using epigenetic variations to diagnose precancerous diseases has higher sensitivity and better specificity than detecting at the gene mutation level.
[0011] The Septin9 gene as a biomarker is based on the methylation status of a specific DNA sequence in the promoter region of the Septin9 gene. Septin9 is a member of the Septin gene family, which consists of at least 13 genes that encode conserved guanosine triphosphatase (GTPase) domains that can bind to cytoskeleton-related proteins that are associated with tumorigenesis. The main functions of Septin gene family proteins are cytokinesis, membrane vesicle transport, membrane fusion, exocytosis, and apoptosis.
[0012] To date, research reports on Septin9 are limited to the detection of esophageal cancer, gastric cancer, colorectal cancer, liver cancer and pancreatic cancer. There are no reports on the detection of cancer risk, precancerous lesions and precancerous diseases for esophageal cancer, gastric cancer, colorectal cancer, liver cancer and pancreatic cancer. Summary of the invention
[0013] The present invention relates to a gene composition, a kit and its use for detecting the risk of digestive tract cancer, digestive tract precancerous lesions and precancerous diseases in an individual by detecting the degree of DNA methylation, as well as a method for performing detection based on the kit.
[0014] Specifically, the present invention relates to the following contents:
[0015] 1. A composition for screening the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases, characterized in that the composition comprises a nucleic acid sequence for detecting the methylation degree in at least one target region of the Septin9 gene;
[0016] Wherein, the target region is a continuous fragment of at least 15 bases selected from SEQ ID No.: 13 or SEQ ID No.: 14, and the length of the fragment is more than 60 bp, preferably 60 to 90 bp;
[0017] The nucleic acid sequence is identical, complementary or hybridizes to the target region; preferably, the nucleic acid sequence hybridizes to the target region under moderately stringent or stringent conditions.
[0018] 2. The composition according to item 1 is characterized in that the nucleic acid sequences are primers and probes, wherein the primers and probes have the following characteristics: they can amplify the methylated target region but cannot amplify the unmethylated target region.
[0019] 3. The composition according to item 2, characterized in that
[0020] The length of the primer is greater than 15 bp, preferably 18 to 24 bp; and
[0021] The length of the probe is greater than 15 bp, preferably 18 to 30 bp.
[0022] 4. The composition according to item 2 or 3, characterized in that the primers and probes for detecting the Septin9 gene are any one or more of compositions 1, 2, 3 and 4;
[0023] Composition 1:
[0024] Forward primer SEQ ID No. 1: 5'-TGTTTGTTAGTCGCGTGCG-3'
[0025] Reverse primer SEQ ID No. 2: 5'-AAATTCTCTATCACCGCCGC-3'
[0026] Probe SEQ ID No. 3: 5′-CGCGCGCTCTACGCCTACAA-3′;
[0027] Composition 2:
[0028] Forward primer SEQ ID No.4: 5'-GTCGCGTTTTTCGTCGTT-3'
[0029] Reverse primer SEQ ID No. 5: 5'-CTAAACACACGACCGAAACG-3'
[0030] Probe SEQ ID No. 6: 5′-CCCGCCTAACCCGCGCCC-3′;
[0031] Composition 3:
[0032] Forward primer SEQ ID No.7: 5'-CGGGCGGAGTAGTTAGTGC-3'
[0033] Reverse primer SEQ ID No. 8: 5'-CTCCCGAACGAATCAAATTCC-3'
[0034] Probe SEQ ID No. 9: 5'-CGCACCCGCACCGACCTCC-3'; and
[0035] Composition 4:
[0036] Forward primer SEQ ID No. 10: 5'-TTCGTTGAGAGCGTCGCG-3'
[0037] Reverse primer SEQ ID No. 11: 5'-GCGCAAAATCTACGCGAATAC-3'
[0038] Probe SEQ ID No. 12: 5'-CCCACGTAAACGACGCGAACACG-3'.
[0039] 5. A kit for screening the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases, characterized in that the kit comprises the composition described in any one of items 1 to 4.
[0040] 6. The kit according to item 5 is characterized in that the digestive tract precancerous lesions and digestive tract precancerous diseases are one or more of the precancerous lesions and precancerous diseases of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer.
[0041] 7. The kit according to item 6 is characterized in that the esophageal precancerous lesions and precancerous diseases include: chronic esophagitis, Barrett's esophagus, esophageal leukoplakia, esophageal diverticulum, achalasia, and reflux esophagitis.
[0042] 8. The kit according to item 6 is characterized in that the gastric precancerous lesions and precancerous diseases include: atrophic gastritis, polyps, gastric ulcers, xanthomas, and intestinal metaplasia.
[0043] 9. The kit according to item 6 is characterized in that the precancerous lesions and precancerous diseases of intestinal cancer include: ulcerative colitis, colorectal polyposis, colorectal adenoma, and Crohn's disease.
[0044] 10. The kit according to item 6 is characterized in that the precancerous lesions and precancerous diseases of liver cancer include: cirrhosis.
[0045] 11. The kit according to item 6 is characterized in that the pancreatic precancerous lesions and precancerous diseases include: mucinous cystadenoma, pancreatitis, pseudocyst, and insulinoma.
[0046] 12. A detection method of the kit according to any one of items 5 to 11, characterized in that it comprises the following steps:
[0047] a) Collecting human samples;
[0048] b) extracting free DNA from the human sample;
[0049] c) converting the DNA with bisulfite;
[0050] d) performing a PCR reaction;
[0051] f) interpreting the results of the PCR reaction products.
[0052] 13. The method according to item 12 is characterized in that the human sample is selected from one or more of cell lines, tissue sections, biopsy tissues, paraffin-embedded tissues, body fluids, feces, colon effluent, urine, plasma, serum, whole blood, separated blood cells, and cells separated from blood.
[0053] 14. The method according to item 12 is characterized in that the human sample is venous blood and plasma drawn from a vein.
[0054] 15. Use of the composition according to any one of items 1 to 4 in the preparation of a kit for screening the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases.
[0055] 16. The use according to item 15 is characterized in that the precancerous lesions and precancerous diseases are one or more of the precancerous lesions and precancerous diseases of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer.
[0056] 17. The use according to item 16 is characterized in that the esophageal precancerous lesions and precancerous diseases include: chronic esophagitis, Barrett's esophagus, esophageal leukoplakia, esophageal diverticulum, achalasia, and reflux esophagitis.
[0057] 18. The use according to item 16 is characterized in that the gastric precancerous lesions and precancerous diseases include: atrophic gastritis, polyps, gastric ulcers, xanthomas, and intestinal metaplasia.
[0058] 19. The use according to item 16 is characterized in that the precancerous lesions and precancerous diseases of intestinal cancer include: ulcerative colitis, colorectal polyposis, colorectal adenoma, and Crohn's disease.
[0059] 20. The use according to item 16, characterized in that the precancerous lesions and precancerous diseases of liver cancer include: cirrhosis.
[0060] 21. The use according to item 16, characterized in that the pancreatic precancerous lesions and precancerous diseases include: mucinous cystadenoma, pancreatitis, pseudocyst, and insulinoma.
[0061] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below can be combined with each other to form new or preferred technical solutions.
[0062] Effects of the Invention
[0063] Although imaging and endoscopy are currently one of the effective methods for screening precancerous diseases of the digestive tract, they are currently unable to meet the needs of a large population due to low compliance and limited domestic medical resources and professional technicians. Traditional tumor markers are currently the most commonly used cancer screening method in addition to imaging and endoscopy, but the detection rate for early cancer is generally around 10-20%, and the detection rate for precancerous lesions and precancerous diseases is even lower. Therefore, compared with imaging, endoscopy and traditional tumor markers, it is necessary to develop an efficient, sensitive, simple and highly compliant detection method for early screening of digestive tract cancer risk, digestive tract precancerous lesions and digestive tract precancerous diseases.
[0064] The present invention utilizes the fact that detecting the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases at the epigenetic variation level has higher sensitivity and better specificity than detecting at the gene mutation level, and develops a method for detecting the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases by detecting Septin9 gene methylation, as well as corresponding compositions, kits and nucleic acid sequences, thereby diagnosing and detecting the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases in a non-invasive manner, efficiently and sensitively at an early stage, greatly improving the detection rate of the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases, and being a very effective supplementary auxiliary detection method for people who reject endoscopic and imaging examinations or are unable to undergo endoscopic and imaging examinations due to special reasons. BRIEF DESCRIPTION OF THE DRAWINGS
[0065] Figure 1 The results show the detection and amplification effects of Septin9 using methylated and non-methylated DNA as templates.
[0066] Figure 2 Methylation of CpG islands is shown.
[0067] Figure 3 It shows the changes in the methylation status of Septin9 during the occurrence of colorectal cancer. DETAILED DESCRIPTION
[0068] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those commonly understood by those skilled in the art. Although a variety of similar or identical methods and materials can be used in experiments or practical applications, the materials and methods are described below. In the event of a conflict, the definitions in this specification shall prevail. In addition, the materials, methods and examples are for illustration only and are not restrictive.
[0069] Other features and advantages of the present invention will be described in detail below.
[0070] definition
[0071] The digestive tract refers to a long muscular tube that starts from the mouth and continues to the pharynx, esophagus, stomach, small intestine, large intestine, and ends at the anus. It includes the mouth, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum) and large intestine (cecum, colon, rectum). There are two types of digestive glands: small digestive glands and large digestive glands. Small digestive glands are scattered in the walls of various parts of the digestive tract. The large digestive glands include three pairs of salivary glands, liver and pancreas, all of which discharge secretions into the digestive tract through ducts.
[0072] Precancerous lesions refer to a stage in the development of cancer, and certain lesions that may become cancerous if they continue to develop. Under the long-term effects of different carcinogenic factors, the body's normal cells first show an increase in cell number, but the cell morphology has not yet changed. Pathologically, this change is called "simple hyperplasia." Later, as the number increases, the difference in cell morphology from that of the tissue of origin (also known as atypia) gradually worsens, but it has not yet developed into cancer. This stage is the precursor stage of cancer and is called "precancerous lesions." In precancerous lesions, although the proliferating cells have a tendency to transform into cancer cells, they have not yet become typical cancers. Moreover, not all precancerous lesions develop into cancer. Most precancerous lesions subside and recover at this point. Only a very small part of precancerous lesions continue to develop and eventually evolve into cancer.
[0073] Precancerous diseases Although some diseases are not malignant tumors themselves, they have the potential to develop into malignant tumors, and patients have an increased risk of developing corresponding malignant tumors. These diseases are called precancerous diseases. Precancerous disease is a clinical concept. It is a class of diseases that include abnormal changes in etiology and pathology, clinical symptoms, physical signs and auxiliary examinations. In fact, the process of cell canceration develops and gradually evolves in stages from carcinogenic factors attacking normal tissue cells to the production of cancer. It usually takes more than 10 years or even longer. Of course, there are also rapid progress. In this long process, precancerous diseases develop into cancer through precancerous rubbing.
[0074] Septin9 gene refers to a member of the Septin gene family, which consists of at least 13 genes, which encode conserved guanosine triphosphatase (GTPase) domains that can bind to cytoskeleton-related proteins, which are associated with tumorigenesis. Members of the Septin gene family are associated with a variety of cellular functions from vesicle transport to cytokinesis, such as cytokinesis, vesicle transport, membrane fusion, exocytosis, and apoptosis. Disruption of the function of Septin9 will lead to incomplete cell division. Septin9 and other proteins have been shown to be fusion partners of the proto-oncogene MLL, which indicates a role in tumorigenesis.
[0075] The target region refers to the target region of the gene, also known as the target gene, that is, the target gene. In molecular genetics, it should not only have the recognition and binding function, but also have the function of expressing the required corresponding function after binding to the site.
[0076] Methylation refers to DNA methylation, a form of DNA chemical modification that can change genetic expression without changing the DNA sequence. DNA methylation refers to the covalent bonding of a methyl group to the 5' carbon position of cytosine in genomic CpG dinucleotides under the action of DNA methyltransferase. DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with proteins, thereby controlling gene expression.
[0077] Nucleic acid refers to a biological macromolecule compound composed of many nucleotides, and is one of the most basic substances of life. Nucleic acid is widely present in all animal and plant cells and microorganisms. Nucleic acid in organisms often combines with proteins to form nucleoproteins. Different nucleic acids have different chemical compositions and nucleotide arrangement sequences. Based on their different chemical compositions, nucleic acids can be divided into ribonucleic acid (RNA for short) and deoxyribonucleic acid (DNA for short). DNA is the main material basis for storing, replicating and transmitting genetic information. RNA plays an important role in the protein synthesis process.
[0078] Oligonucleotide is a general term for a class of short-chain nucleotides with less than 20 bases (including nucleotides in deoxyribonucleic acid DNA or ribonucleic acid RNA). Oligonucleotides can be easily linked to their complementary pairs, so they are often used as probes to determine the structure of DNA or RNA, and are often used in gene chips, electrophoresis, fluorescence in situ hybridization and other processes.
[0079] Primers refer to macromolecules with specific nucleotide sequences that are stimulated to synthesize at the start of nucleotide polymerization and are covalently linked to the reactants. Such molecules are called primers. Primers are usually two artificially synthesized oligonucleotide sequences, one primer is complementary to a DNA template strand at one end of the target region, and the other primer is complementary to another DNA template strand at the other end of the target region. Their function is to serve as the starting point for nucleotide polymerization, and nucleic acid polymerase can start synthesizing new nucleic acid chains from their 3' end. In vitro artificially designed primers are widely used in polymerase chain reactions, sequencing, and probe synthesis.
[0080] The probe is a single-stranded or double-stranded DNA with a length ranging from tens to hundreds or even thousands of base pairs, which is labeled with a special tracer (such as an isotope, enzyme or colored group); under appropriate pH, temperature and ionic strength, the DNA probe can use the molecular denaturation, renaturation and high accuracy of base complementary pairing to hydrogen bond (hybridize) with the complementary non-labeled single-stranded DNA or RNA in the sample to be tested to form a double-stranded complex (hybrid). After washing away the unpaired probe, the hybridization reaction results can be detected by detection systems such as radioautography or enzyme-linked reaction.
[0081] The forward primer is the primer located upstream of the DNA double strand, which is extended uninterruptedly along the negative strand. The negative strand is the nonsense strand, also known as the non-coding strand, which is complementary to the positive strand. The primer that binds to this strand is the forward primer.
[0082] The reverse primer is the primer located at the downstream of the DNA double strand, which is extended continuously along the positive strand. The positive strand is the sense strand, also known as the coding strand, which is generally located at the top of the double-stranded DNA, and the direction from left to right is 5'-3'.
[0083] Cell-free DNA (cfDNA) refers to circulating free DNA or cell-free DNA, which is degraded DNA fragments released into the plasma. Tumor-derived cfDNA can reveal tumor-related mutations, loss of heterozygosity (LOH), gene amplification, oncovirus DNA, and hypermethylation of the promoter region of tumor suppressor genes, thus making it possible to study tumor DNA under non-invasive conditions.
[0084] The present invention relates to the field of biomedical technology, and in particular, to a composition for screening the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases. In the present invention, the composition is used to detect the degree of methylation of the Septin9 gene to detect the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases, thereby preventing and intervening in digestive tract precancerous diseases at an early stage.
[0085] In a specific embodiment of the present invention, a composition comprises a nucleic acid sequence for detecting the degree of methylation in at least one target region of the Septin9 gene; wherein the target region is a continuous fragment of at least 15 bases in length selected from SEQ ID No.: 13 or SEQ ID No.: 14, respectively, and the length of the fragment is more than 60 bp, preferably 60 to 90 bp; the nucleic acid sequence is identical, complementary or hybridizes to the target region; preferably, the nucleic acid sequence hybridizes to the target region under moderately stringent or stringent conditions.
[0086] In a specific embodiment of the present invention, a composition comprises a nucleic acid sequence for detecting the degree of methylation in at least one target region of the Septin9 gene; wherein the target region is a continuous fragment of at least 15 bases selected from SEQ ID No.: 13 or SEQ ID No.: 14, and the length of the fragment is more than 60 bp, preferably 60 to 90 bp; the nucleic acid sequence is identical, complementary or hybridizes to the target region; preferably, the nucleic acid sequence hybridizes to the target region under moderately stringent or stringent conditions. The nucleic acid sequence is a primer and a probe, wherein the primer and the probe have the following characteristics: the methylated target region can be amplified, but the unmethylated target region cannot be amplified.
[0087] In a specific embodiment of the present invention, a composition comprises a nucleic acid sequence for detecting the degree of methylation in at least one target region of the Septin9 gene; wherein the target region is a continuous fragment of at least 15 bases selected from SEQ ID No.: 13 or SEQ ID No.: 14, respectively, and the length of the fragment is 60 bp or more, preferably 60 to 90 bp; the nucleic acid sequence is identical, complementary or hybridized to the target region; preferably, the nucleic acid sequence hybridizes to the target region under moderately stringent or stringent conditions. The nucleic acid sequence is a primer and a probe, wherein the primer and the probe have the following characteristics: the methylated target region can be amplified, but the unmethylated target region cannot be amplified. The length of the primer is 15 bp or more, preferably 18 to 24 bp; and the length of the probe is 15 bp or more, preferably 18 to 30 bp.
[0088] In a specific embodiment of the present invention, a composition comprises a nucleic acid sequence for detecting the degree of methylation in at least one target region of the Septin9 gene; wherein the target region is a continuous fragment of at least 15 bases selected from SEQ ID No.: 13 or SEQ ID No.: 14, and the length of the fragment is more than 60 bp, preferably 60 to 90 bp; the nucleic acid sequence is identical, complementary or hybridized to the target region; preferably, the nucleic acid sequence hybridizes to the target region under moderately stringent or stringent conditions. The nucleic acid sequence is a primer and a probe, wherein the primer and the probe have the following characteristics: the methylated target region can be amplified, but the unmethylated target region cannot be amplified. The primer and the probe are any one or more of compositions 1, 2, 3 and 4:
[0089] Composition 1:
[0090] Forward primer SEQ ID No. 1: 5'-TGTTTGTTAGTCGCGTGCG-3'
[0091] Reverse primer SEQ ID No. 2: 5'-AAATTCTCTATCACCGCCGC-3'
[0092] Probe SEQ ID No. 3: 5′-CGCGCGCTCTACGCCTACAA-3′;
[0093] Composition 2:
[0094] Forward primer SEQ ID No.4: 5'-GTCGCGTTTTTCGTCGTT-3'
[0095] Reverse primer SEQ ID No. 5: 5'-CTAAACACACGACCGAAACG-3'
[0096] Probe SEQ ID No. 6: 5′-CCCGCCTAACCCGCGCCC-3′;
[0097] Composition 3:
[0098] Forward primer SEQ ID No.7: 5'-CGGGCGGAGTAGTTAGTGC-3'
[0099] Reverse primer SEQ ID No. 8: 5'-CTCCCGAACGAATCAAATTCC-3'
[0100] Probe SEQ ID No. 9: 5'-CGCACCCGCACCGACCTCC-3'; and
[0101] Composition 4:
[0102] Forward primer SEQ ID No. 10: 5'-TTCGTTGAGAGCGTCGCG-3'
[0103] Reverse primer SEQ ID No. 11: 5'-GCGCAAAATCTACGCGAATAC-3'
[0104] Probe SEQ ID No. 12: 5'-CCCACGTAAACGACGCGAACACG-3'.
[0105] In a specific embodiment of the present invention, a composition comprises a nucleic acid sequence for detecting the degree of methylation in at least one target region of the Septin9 gene; wherein the target region is a continuous fragment of at least 15 bases selected from SEQ ID No.: 13 or SEQ ID No.: 14, respectively, and the length of the fragment is 60 bp or more, preferably 60 to 90 bp; the nucleic acid sequence is identical, complementary or hybridized to the target region; preferably, the nucleic acid sequence hybridizes to the target region under moderately stringent or stringent conditions. The nucleic acid sequence is a primer and a probe, wherein the primer and the probe have the following characteristics: the methylated target region can be amplified, but the unmethylated target region cannot be amplified. The length of the primer is 15 bp or more, preferably 18 to 24 bp; and the length of the probe is 15 bp or more, preferably 18 to 30 bp. The primer and the probe are any one or more of compositions 1, 2, 3 and 4:
[0106] Composition 1:
[0107] Forward primer SEQ ID No. 1: 5'-TGTTTGTTAGTCGCGTGCG-3'
[0108] Reverse primer SEQ ID No. 2: 5'-AAATTCTCTATCACCGCCGC-3'
[0109] Probe SEQ ID No. 3: 5′-CGCGCGCTCTACGCCTACAA-3′;
[0110] Composition 2:
[0111] Forward primer SEQ ID No.4: 5'-GTCGCGTTTTTCGTCGTT-3'
[0112] Reverse primer SEQ ID No. 5: 5'-CTAAACACACGACCGAAACG-3'
[0113] Probe SEQ ID No. 6: 5′-CCCGCCTAACCCGCGCCC-3′;
[0114] Composition 3:
[0115] Forward primer SEQ ID No.7: 5'-CGGGCGGAGTAGTTAGTGC-3'
[0116] Reverse primer SEQ ID No. 8: 5'-CTCCCGAACGAATCAAATTCC-3'
[0117] Probe SEQ ID No. 9: 5'-CGCACCCGCACCGACCTCC-3'; and
[0118] Composition 4:
[0119] Forward primer SEQ ID No. 10: 5'-TTCGTTGAGAGCGTCGCG-3'
[0120] Reverse primer SEQ ID No. 11: 5'-GCGCAAAATCTACGCGAATAC-3'
[0121] Probe SEQ ID No. 12: 5'-CCCACGTAAACGACGCGAACACG-3'.
[0122] In the present invention, the nucleic acid includes at least 15 oligonucleotide fragments of Septin9, wherein the oligonucleotide contains at least one CpG dinucleotide sequence. Preferably, the oligonucleotide fragment of Septin9 contains at least 15 nucleotides and their complementary sequences that are identical, complementary, or hybridize under moderately stringent or stringent conditions to a sequence selected from SEQ ID No.: 13 or SEQ ID No.: 14 or its variants. More preferably, the oligonucleotide fragment of Septin9 contains sequences that are identical, complementary, or hybridize under moderately stringent or stringent conditions to a sequence selected from SEQ ID No.: 1 to SEQ ID No.: 12 and their complementary sequences. The nucleic acid sequence used to detect whether methylation exists in at least one target region of the Septin9 gene and its oligonucleotide fragments includes: a fragment of at least 9 bases in length that is identical, complementary, or hybridizes under moderately stringent or stringent conditions to a continuous sequence selected from SEQ ID NO.: 13 or SEQ ID No.: 14 and its variants.
[0123] SEQ ID No.: 13 The sequence is as follows:
[0124]
[0125] A further preferred SEQ ID No.: 14 sequence is shown below:
[0126]
[0127] In the present invention, the composition can specifically detect the degree of methylation in at least one target region of the Septin9 gene. The advantage of the composition is that it has a high detection rate for digestive tract cancer, and also has a high detection rate for precancerous lesions and precancerous diseases. However, for people without digestive tract lesions, the false positive rate can be controlled within 5%.
[0128] The present invention also relates to a kit for screening the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases. The risk of cancer refers to the possibility that a group without precancerous diseases, precancerous lesions or cancer whose gene methylation abnormalities are detected by the detection system of the present application will suffer from precancerous diseases, precancerous lesions or further develop cancer in the future.
[0129] In a specific embodiment of the present invention, the kit comprises the composition described in any one of the above embodiments.
[0130] In a specific embodiment of the present invention, the digestive tract precancerous lesions and digestive tract precancerous diseases screened by the kit are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases.
[0131] In a specific embodiment of the present invention, the digestive tract precancerous lesions and digestive tract precancerous diseases screened by the kit are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The esophageal cancer precancerous lesions and precancerous diseases include: chronic esophagitis, Barrett's esophagus, esophageal leukoplakia, esophageal diverticulum, achalasia, reflux esophagitis.
[0132] In a specific embodiment of the present invention, the digestive tract precancerous lesions and digestive tract precancerous diseases screened by the kit are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The gastric cancer precancerous lesions and precancerous diseases include: atrophic gastritis, polyps, gastric ulcers, xanthomas, intestinal metaplasia.
[0133] In a specific embodiment of the present invention, the digestive tract precancerous lesions and digestive tract precancerous diseases screened by the kit are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The intestinal cancer precancerous lesions and precancerous diseases include: ulcerative colitis, colorectal polyposis, colorectal adenoma, Crohn's disease.
[0134] In a specific embodiment of the present invention, the digestive tract precancerous lesions and digestive tract precancerous diseases screened by the kit are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The liver cancer precancerous lesions and precancerous diseases include: cirrhosis.
[0135] In a specific embodiment of the present invention, the digestive tract precancerous lesions and digestive tract precancerous diseases screened by the kit are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The pancreatic cancer precancerous lesions and precancerous diseases include: mucinous cystadenoma, pancreatitis, pseudocyst, insulinoma.
[0136] In the present invention, the digestive tract precancerous lesions and precancerous diseases include, but are not limited to, chronic esophagitis, esophageal squamous epithelial atypical hyperplasia, Barrett's esophagus, atrophic gastritis, gastric ulcer, gastric polyp, intestinal polyp, intestinal adenoma, cirrhosis, pancreatitis, etc.
[0137] According to the Guidelines for Early Colorectal Cancer Screening and Endoscopic Diagnosis and Treatment in China (2014. Beijing), one of the risk factors for colorectal cancer is inflammatory bowel disease. This disease is a clear risk factor for colorectal cancer. Some studies have shown that about 20% of patients with inflammatory bowel disease may develop colorectal cancer within 10 years of onset, which is 2-4 times the risk of the normal population. Another meta-analysis showed that the standardized incidence ratio of patients with ulcerative colitis was 2.4 after an average follow-up of 14 years. In addition, the guidelines clearly point out that low-grade intraepithelial neoplasia is equivalent to the original mild and moderate dysplasia, which is a precancerous lesion, while high-grade intraepithelial neoplasia includes severe dysplasia, carcinoma in situ, carcinoma in situ can invade and intramucosal cancer, which is already a clear colorectal cancer. Colorectal adenomas can be divided into tubular adenomas, tubulovillous adenomas and villous adenomas, with the highest rate of carcinoma in villous adenomas and the lowest rate in tubular adenomas. Most colorectal cancers are formed through the adenoma-adenocarcinoma pathway. The guidelines recommend colorectal cancer screening for people including, but not limited to, the following groups: (1) People with a history of precancerous diseases such as colorectal adenomatous polyps, ulcerative colitis, and Crohn's disease.
[0138] The development process of gastric cancer is generally as follows: normal gastric mucosa → superficial gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → gastric cancer. The American Society for Gastrointestinal Endoscopy (ASGE) pointed out in its “Endoscopic Management of Gastric Cancer and Precancerous Lesions” that precancerous diseases include gastric polyps, intestinal metaplasia, and dysplasia. The “China Consensus on Early Gastric Cancer Screening and Endoscopic Diagnosis and Treatment (2014, Changsha)” determined that people aged ≥40 years who have had precancerous diseases of the stomach such as chronic atrophic gastritis, gastric ulcer, gastric polyps, postoperative residual stomach, hypertrophic gastritis, pernicious anemia, etc. are all high-risk groups for gastric cancer screening.
[0139] The "Expert Consensus on Early Esophageal Cancer Screening and Endoscopic Diagnosis and Treatment in China (2014, Beijing)" points out that esophageal precancerous diseases refer to benign diseases that are related to esophageal cancer and have a certain rate of canceration, including chronic esophagitis, Barrett's esophagus, esophageal leukoplakia, esophageal diverticulum, achalasia, reflux esophagitis, benign esophageal strictures caused by various reasons, etc. Precancerous lesions refer to pathological changes that have been proven to be closely related to the occurrence of esophageal cancer. Esophageal squamous epithelial dysplasia is closely related to the occurrence of squamous cell carcinoma and is a precancerous lesion. Barrett's esophagus-related dysplasia is a precancerous lesion of adenocarcinoma. The guidelines point out that people over 40 years old who have esophageal precancerous diseases or precancerous lesions are at high risk of esophageal cancer.
[0140] The main high-risk factors for liver cancer in my country are: people with hepatitis B / C or alcoholic cirrhosis, aflatoxin exposure history, and a history of drinking water contamination are at high risk of liver cancer. The NCCN Clinical Practice Guidelines in Oncology (2017) pointed out that people with cirrhosis are at risk of liver cancer and should undergo regular ultrasound or AFP examinations.
[0141] "Pay Attention to the Recognition and Treatment of Pancreatic Precancerous Lesions" (Surgical Theory and Practice, Vol. 5, Issue 14, 2009) and "Diagnosis and Treatment of Pancreatic Precancerous Lesions" (Chinese Journal of Digestion, Vol. 28, Issue 9, September 2008) both point out that pancreatic cancer is a common malignant tumor of the digestive system, with a 5-year survival rate of only 3%, and a median survival time of < 6 months. Pancreatic cancer has an insidious onset, atypical early symptoms and rapid progression, and most patients are in the late stage when they seek medical treatment. Early diagnosis and comprehensive treatment have become the key to improving the treatment effect of pancreatic cancer. Precancerous lesions are the initial stage of the development of malignant tumors and the best time to start treatment and block malignant transformation. Precancerous lesions of pancreatic cancer include pancreatic intraepithelial neoplasia, chronic pancreatitis, intraductal papillary mucinous neoplasms, and mucinous cystic neoplasms.
[0142] In the present invention, the kit has higher sensitivity and better specificity, and can diagnose and detect the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases in a non-invasive manner and at an early stage with high efficiency and sensitivity, thus greatly improving the detection rate of the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases. For people who reject endoscopy and imaging examinations or cannot undergo endoscopy and imaging examinations due to special reasons, it is a very effective supplementary auxiliary detection method.
[0143] The present invention also relates to a detection method of the kit in the above embodiment.
[0144] In a specific embodiment of the present invention, the method comprises the following steps: a) collecting a human sample; b) extracting free DNA from the human sample; c) converting the DNA with bisulfite; d) performing a PCR reaction; and e) interpreting the results of the product of the PCR reaction.
[0145] In a specific embodiment of the present invention, the method comprises the following steps: a) collecting human samples; b) extracting free DNA from the human samples; c) converting the DNA with bisulfite; d) performing PCR reaction; e) interpreting the results of the products of the PCR reaction. The human samples are selected from one or more of cell lines, tissue sections, biopsy tissues, paraffin-embedded tissues, body fluids, feces, colon effluent, urine, plasma, serum, whole blood, separated blood cells, and cells separated from blood.
[0146] In a specific embodiment of the present invention, the method comprises the following steps: a) collecting human samples; b) extracting free DNA from the human samples; c) converting the DNA with bisulfite; d) performing PCR reaction; e) interpreting the results of the PCR reaction products. The human samples are venous blood and plasma drawn from veins.
[0147] In the present invention, the method also includes determining the degree of methylation in at least one target region of the Septin9 gene and its fragments in the biological sample separated from the individual, and detecting the precancerous disease of the digestive tract in the individual through the methylation detection result of Septin9. The method also includes using a reagent (e.g., bisulfite) to convert the unmethylated cytosine base at position 5 of the DNA into uracil or other bases that are detectably different from cytosine in terms of hybridization performance; contacting the Septin9 or its fragments treated with the reagent with an amplification enzyme and a primer so that the treated gene or fragment is amplified to produce an amplification product or is not amplified; detecting the amplification product with a probe; and determining the degree of methylation of at least one CpG dinucleotide of the Septin9 gene DNA sequence based on whether the amplification product exists. The methylation state of at least one CpG dinucleotide of the Septin9 gene DNA sequence is determined by the cycle threshold Ct value of the polymerase chain reaction.
[0148] In the present invention, the method for detecting the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases in individuals using the kit has the characteristics of high sensitivity and good specificity. The method is a non-invasive method, and can be used for screening and detection of high-risk groups of digestive tract cancer who are resistant to endoscopy or imaging or cannot undergo endoscopy or imaging examinations due to special reasons.
[0149] The present invention also relates to a use of the composition in the above embodiment in preparing a kit for screening the risk of digestive tract cancer, digestive tract precancerous lesions and digestive tract precancerous diseases.
[0150] In a specific embodiment of the present invention, the precancerous lesions and precancerous diseases are one or more of the precancerous lesions and precancerous diseases of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer.
[0151] In a specific embodiment of the present invention, the precancerous lesions and precancerous diseases are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The precancerous lesions and precancerous diseases of esophageal cancer include: chronic esophagitis, Barrett's esophagus, esophageal leukoplakia, esophageal diverticulum, achalasia, reflux esophagitis.
[0152] In a specific embodiment of the present invention, the precancerous lesions and precancerous diseases are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The gastric cancer precancerous lesions and precancerous diseases include: atrophic gastritis, polyps, gastric ulcers, xanthomas, intestinal metaplasia.
[0153] In a specific embodiment of the present invention, the precancerous lesions and precancerous diseases are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The intestinal cancer precancerous lesions and precancerous diseases include: ulcerative colitis, colorectal polyposis, colorectal adenoma, Crohn's disease.
[0154] In a specific embodiment of the present invention, the precancerous lesions and precancerous diseases are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The precancerous lesions and precancerous diseases of liver cancer include: cirrhosis.
[0155] In a specific embodiment of the present invention, the precancerous lesions and precancerous diseases are one or more of esophageal cancer, gastric cancer, intestinal cancer, liver cancer and pancreatic cancer precancerous lesions and precancerous diseases. The precancerous lesions and precancerous diseases of pancreatic cancer include: mucinous cystadenoma, pancreatitis, pseudocyst, insulinoma.
[0156] In the present invention, the digestive tract precancerous lesions and precancerous diseases include, but are not limited to, chronic esophagitis, esophageal squamous epithelial atypical hyperplasia, Barrett's esophagus, atrophic gastritis, gastric ulcer, gastric polyp, intestinal polyp, intestinal adenoma, cirrhosis, pancreatitis, etc.
[0157] The following are examples of the compositions, kits, nucleic acid sequences and detection methods of the present application. It will be appreciated that, given the general description provided above, a variety of other embodiments may be implemented.
[0158] The present invention is further described below in conjunction with examples. It should be understood that the examples are only used to further illustrate and explain the present invention, and are not intended to limit the present invention.
[0159] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989).
[0160] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0161] Example
[0162] Example 1 :Septin9 gene methylation detection method
[0163] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template and 450 nM primers (composition 1: forward primer SEQ ID No. 1 and reverse primer SEQ ID No. 2), 225 nM probe (composition 1: probe SEQ ID No. 3), 1 U Taq polymerase, 200 μM of each dNTP, 4.5 mM MgCl 2 and 2X PCR buffer to a final volume of 50 μl. Samples were pre-cycled at 94°C for 20 minutes, followed by 45 cycles of annealing at 62°C for 5 seconds, annealing at 55.5°C for 35 seconds, and denaturation at 93°C for 30 seconds.
[0164] PCR detection using artificial methylated oligonucleotide template and artificial non-methylated oligonucleotide template, such as Figure 1 As shown, the artificial methylated oligonucleotide template was amplified, while the artificial non-methylated oligonucleotide template was not amplified, indicating that the primers and probes were correct and could be used for the detection of methylated Septin9.
[0165] Example 2 : Detection of esophageal precancerous lesions and precancerous diseases
[0166] The detection of esophageal precancerous lesions and precancerous diseases currently still relies mainly on esophagoscopy. However, the compliance with esophagoscopy is generally low everywhere, which limits the early screening of people at high risk of esophageal cancer.
[0167] A total of 1,150 asymptomatic people were tested for Septin9. All of the 1,150 asymptomatic people had varying degrees of resistance to endoscopy or imaging according to questionnaires. The test sample was plasma (1.2 to 3.5 mL), and free DNA was extracted from each sample. The DNA extraction can be carried out by any standard means in the prior art. Specifically, in this embodiment, all sample DNA was extracted using the nucleic acid extraction reagent of Boercheng (Beijing) Technology Co., Ltd.
[0168] Then, the DNA sample is pretreated so that the 5' unmethylated cytosine base is converted into uracil, thymine or another base that is different from cytosine in hybridization behavior. In this embodiment, the pretreatment is achieved by treating with a bisulfite reagent. The modification of bisulfite DNA is carried out by using a nucleic acid extraction reagent from Boercheng (Beijing) Technology Co., Ltd.
[0169] Then, the detection system of Example 1 was added to the pre-treated DNA samples of the 1150 asymptomatic people to detect the Septin 9 gene. Real-time PCR was performed on the bisulfite-converted DNA.
[0170] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template and 450 nM primers (using composition 2: forward primer SEQ ID No. 4 and reverse primer SEQ ID No. 5), 225 nM probe (using composition 2: probe SEQ ID No. 6), 1 U Taq polymerase, 200 μm of each dNTP, 4.5 mM MgCl 2 and 2X PCR buffer to a final volume of 50 μl. Amplify samples with pre-cycling at 94°C for 20 min, followed by 45 cycles of annealing at 62°C for 5 sec, annealing at 55.5°C for 35 sec, and denaturation at 93°C for 30 sec.
[0171] Finally, the results of 1150 asymptomatic people were interpreted according to the Cutoff value of the kit (≤41.0), of which 52 cases were positive for Septin9 methylation, with a positive rate of 4.35%. After further psychological counseling and medical popularization, 41 of the 52 positive subjects completed endoscopic examinations, of which 40 were positive for endoscopic examinations, with an overall positive rate of 97.60%. Among them, the number of samples with lesions in the esophagus was 12, and the types of diseases are shown in Table 1 below. The results of gastroscopy and colonoscopy are described in Examples 3 and 4.
[0172] Table 1. Septin 9-positive esophagoscopy results in 1150 asymptomatic subjects.
[0173]
[0174]
[0175] Through Septin9 screening of 1,150 asymptomatic people, Septin9 methylation detection provides a safe and non-invasive auxiliary diagnostic method for early screening of esophageal cancer precancerous lesions and precancerous diseases for high-risk people who refuse endoscopic examinations. Among the 1,150 asymptomatic people, 12 of them were tested through Septin9, and the risk of esophageal cancer was effectively reduced through early intervention. Without this test, high-risk people with esophageal cancer who refuse endoscopic examinations would not have the opportunity to effectively intervene in precancerous diseases in advance.
[0176] Example 3 :Detection of gastric precancerous lesions and precancerous diseases
[0177] The discovery of gastric precancerous lesions and precancerous diseases currently still relies mainly on gastroscopy. However, the compliance with gastroscopy is generally low everywhere, which limits the early screening of high-risk groups for gastroscopy.
[0178] A total of 1,150 asymptomatic people were tested for Septin9. All of the 1,150 asymptomatic people had varying degrees of resistance to endoscopy or imaging according to questionnaires. The test sample was plasma (1.2 to 3.5 mL), and free DNA was extracted from each sample. The DNA extraction can be carried out by any standard means in the prior art. Specifically, in this embodiment, all sample DNA was extracted using the nucleic acid extraction reagent of Boercheng (Beijing) Technology Co., Ltd.
[0179] Then, the DNA sample is pretreated so that the 5' unmethylated cytosine base is converted into uracil, thymine or another base that is different from cytosine in hybridization behavior. In this embodiment, the pretreatment is achieved by treating with a bisulfite reagent. The modification of bisulfite DNA is carried out by using a nucleic acid extraction reagent from Boercheng (Beijing) Technology Co., Ltd.
[0180] Then, the detection system of Example 1 was added to the pre-treated DNA samples of the 1150 asymptomatic people to detect the Septin 9 gene. Real-time PCR was performed on the bisulfite-converted DNA.
[0181] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template and 450 nM primers (using composition 3: forward primer SEQ ID No. 7 and reverse primer SEQ ID No. 8), 225 nM probe (using composition 3: probe SEQ ID No. 9), 1 U Taq polymerase, 200 μm of each dNTP, 4.5 mM MgCl 2 and 2X PCR buffer to a final volume of 50 μl. Amplify samples with pre-cycling at 94°C for 20 min, followed by 45 cycles of annealing at 62°C for 5 sec, annealing at 55.5°C for 35 sec, and denaturation at 93°C for 30 sec.
[0182] Finally, the results of 1,150 asymptomatic people were interpreted according to the cutoff value of the test kit (≤41.0), of which 52 were positive for Septin9 methylation, with a positive rate of 4.35%. After further psychological counseling and medical popularization, 41 of the 52 positive subjects completed endoscopic examinations, of which 40 were positive, with an overall positive rate of 97.60%. Among them, the number of samples with gastric lesions was 36, and the types of diseases are shown in Table 2 below.
[0183] Table 2. Septin9-positive gastroscopy results in 1150 asymptomatic subjects.
[0184]
[0185]
[0186] Through Septin9 screening of 1,150 asymptomatic people, Septin9 methylation testing provides a safe and non-invasive auxiliary diagnostic method for early screening of gastric precancerous lesions and precancerous diseases for high-risk people with gastric cancer who refuse endoscopic examinations. Among the 1,150 asymptomatic people, 36 of them were tested through Septin9, and the risk of gastric cancer was effectively reduced through early intervention. Without this test, high-risk people with gastric cancer who refuse endoscopic examinations would not have the opportunity to effectively intervene in precancerous diseases in advance.
[0187] Example 4 : Detection of colorectal cancer precancerous lesions and precancerous diseases
[0188] The detection of colorectal precancerous lesions and precancerous diseases currently still relies mainly on colonoscopy. However, the compliance with colonoscopy is generally low everywhere, which limits the early screening of people at high risk of colorectal cancer.
[0189] A total of 1,150 asymptomatic people were tested for Septin9. All of the 1,150 asymptomatic people had varying degrees of resistance to endoscopy or imaging according to questionnaires. The test sample was plasma (1.2 to 3.5 mL), and free DNA was extracted from each sample. The DNA extraction can be carried out by any standard means in the prior art. Specifically, in this embodiment, all sample DNA was extracted using the nucleic acid extraction reagent of Boercheng (Beijing) Technology Co., Ltd.
[0190] Then, the DNA sample is pretreated so that the 5' unmethylated cytosine base is converted into uracil, thymine or another base that is different from cytosine in hybridization behavior. In this embodiment, the pretreatment is achieved by treating with a bisulfite reagent. The modification of bisulfite DNA is carried out by using a nucleic acid extraction reagent from Boercheng (Beijing) Technology Co., Ltd.
[0191] Then, the detection system of Example 1 was added to the pre-treated DNA samples of the 1150 asymptomatic people to detect the Septin 9 gene. Real-time PCR was performed on the bisulfite-converted DNA.
[0192] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template and 450 nM primers (using composition 4: forward primer SEQ ID No. 10 and reverse primer SEQ ID No. 11), 225 nM probe (using composition 4: probe SEQ ID No. 12), 1 U Taq polymerase, 200 μm of each dNTP, 4.5 mM MgCl 2 and 2X PCR buffer to a final volume of 50 μl. Amplify samples with pre-cycling at 94°C for 20 min, followed by 45 cycles of annealing at 62°C for 5 sec, annealing at 55.5°C for 35 sec, and denaturation at 93°C for 30 sec.
[0193] Finally, the results of 1,150 asymptomatic people were interpreted according to the cutoff value of the kit (≤41.0), of which 52 were positive for Septin9 methylation, with a positive rate of 4.35%. After further psychological counseling and medical popularization, 41 of the 52 positive subjects completed endoscopic examinations, of which 40 were positive, with an overall positive rate of 97.60%. Among them, the number of samples with intestinal lesions was 19, and the types of diseases are shown in Table 3 below.
[0194] Table 3. Septin 9 positive colonoscopy results in 1150 asymptomatic subjects.
[0195]
[0196]
[0197] Through Septin9 screening of 1,150 asymptomatic people, Septin9 methylation testing provides a safe and non-invasive auxiliary diagnostic method for early screening of colorectal precancerous lesions and precancerous diseases for people at high risk of colorectal cancer who refuse endoscopic examinations. Among the 1,150 asymptomatic people, 19 of them were tested through Septin9, and the risk of colorectal cancer was effectively reduced through early intervention. Without this test, people at high risk of colorectal cancer who refuse endoscopic examinations would not have the opportunity to effectively intervene in precancerous diseases in advance.
[0198] Example 5 : Detection of liver cancer precancerous lesions and precancerous diseases
[0199] A total of 1459 asymptomatic people were tested for Septin9. All of them had varying degrees of resistance to imaging or endoscopy after questionnaire survey. The test sample was plasma (1.2-3.5 mL), and free DNA was extracted from each sample. The DNA extraction can be carried out by any standard means in the prior art. Specifically, in this embodiment, all sample DNA was extracted using the nucleic acid extraction reagent of Boercheng (Beijing) Technology Co., Ltd.
[0200] Then, the DNA sample is pretreated so that the 5' unmethylated cytosine base is converted into uracil, thymine or another base that is different from cytosine in hybridization behavior. In this embodiment, the pretreatment is achieved by treating with a bisulfite reagent. The modification of bisulfite DNA is carried out by using a nucleic acid extraction reagent from Boercheng (Beijing) Technology Co., Ltd.
[0201] Then, the detection system of Example 1 was added to the pre-treated DNA samples of the 1459 asymptomatic people to detect the Septin 9 gene. Real-time PCR was performed on the bisulfite-converted DNA.
[0202] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template and 450 nM primers (using composition 1: forward primer SEQ ID No. 1 and reverse primer SEQ ID No. 2), 225 nM probe (using composition 1: probe SEQ ID No. 3), 1 U Taq polymerase, 200 μm of each dNTP, 4.5 mM MgCl 2 and 2X PCR buffer to a final volume of 50 μl. Amplify samples with pre-cycling at 94°C for 20 min, followed by 45 cycles of annealing at 62°C for 5 sec, annealing at 55.5°C for 35 sec, and denaturation at 93°C for 30 sec.
[0203] Finally, the results of 1459 asymptomatic people were interpreted according to the cutoff value of the kit (≤41.0), of which 68 cases were positive for Septin9 methylation, with a positive rate of 4.66%. Among the 68 positive subjects, 49 further completed ultrasound examinations, including 39 cases of liver cirrhosis, with an overall positive rate of 79.59%. The types of diseases are shown in Table 4 below.
[0204] Table 4. Septin 9 positive ultrasound results in 1459 asymptomatic subjects.
[0205]
[0206]
[0207]
[0208] Through Septin9 screening of 1,459 asymptomatic volunteers, Septin9 methylation testing provides a safe and non-invasive auxiliary diagnostic method for early screening of liver cancer precancerous lesions and precancerous diseases for high-risk groups of liver cancer who reject imaging examinations. Among the 1,459 asymptomatic people, 39 of them were tested through Septin9, and the risk of liver cancer transformation was effectively reduced through early intervention. Without this test, high-risk groups of liver cancer who reject imaging examinations would have no chance to effectively intervene in precancerous diseases in advance.
[0209] Example 6 : Detection of pancreatic precancerous disease
[0210] A total of 1,247 asymptomatic people were tested for Septin9. All of them had varying degrees of resistance to imaging or endoscopy after questionnaire survey. The test sample was plasma (1.2-3.5 mL), and free DNA was extracted from each sample. The DNA extraction can be carried out by any standard means in the prior art. Specifically, in this embodiment, all sample DNA was extracted using the nucleic acid extraction reagent of Boercheng (Beijing) Technology Co., Ltd.
[0211] Then, the DNA sample is pretreated so that the 5' unmethylated cytosine base is converted into uracil, thymine or another base that is different from cytosine in hybridization behavior. In this embodiment, the pretreatment is achieved by treating with a bisulfite reagent. The modification of bisulfite DNA is carried out by using a nucleic acid extraction reagent from Boercheng (Beijing) Technology Co., Ltd.
[0212] Then, the detection system of Example 1 was added to the pre-treated DNA samples of the 1247 asymptomatic people to detect the Septin 9 gene. Real-time PCR was performed on the bisulfite-converted DNA.
[0213] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template and 450 nM primers (using composition 2: forward primer SEQ ID No. 4 and reverse primer SEQ ID No. 5), 225 nM probe (using composition 2: probe SEQ ID No. 6), 1 U Taq polymerase, 200 μm of each dNTP, 4.5 mM MgCl 2 and 2X PCR buffer to a final volume of 50 μl. Amplify samples with pre-cycling at 94°C for 20 min, followed by 45 cycles of annealing at 62°C for 5 sec, annealing at 55.5°C for 35 sec, and denaturation at 93°C for 30 sec.
[0214] Finally, the results of 1247 asymptomatic people were interpreted according to the cutoff value of the kit (≤41.0), of which 62 cases were positive for Septin9 methylation, with a positive rate of 4.97%. Among the 62 positive subjects, 52 further completed ultrasound examinations, including 34 cases of pancreatic lesions, with an overall positive rate of 79.59%. The types of diseases are shown in Table 5 below.
[0215] Table 5. Septin 9 positive imaging results in 1247 asymptomatic subjects.
[0216]
[0217]
[0218] Through Septin9 screening of 1,247 asymptomatic volunteers, Septin9 methylation testing provides a safe and non-invasive auxiliary diagnostic method for early screening of pancreatic precancerous lesions and precancerous diseases for high-risk groups of pancreatic cancer who reject imaging examinations. Among the 1,247 asymptomatic people, 29 of them were tested through Septin9, and the risk of pancreatic cancer transformation was effectively reduced through early intervention. Without this test, high-risk groups of pancreatic cancer who reject imaging examinations would have no chance to effectively intervene in precancerous diseases in advance.
[0219] Example 7 : False Positive
[0220] A total of 100 normal volunteers were tested for Septin9, and all of them were tested using imaging or endoscopy to determine that they had no digestive tract cancer, precancerous disease, or precancerous lesions. The test sample was plasma (1.2-3.5 mL), and free DNA was extracted from each sample. The DNA extraction can be performed by any standard means in the prior art. Specifically, in this embodiment, all sample DNA was extracted using the nucleic acid extraction reagent of Boercheng (Beijing) Technology Co., Ltd.
[0221] Then, the DNA sample is pretreated so that the 5' unmethylated cytosine base is converted into uracil, thymine or another base that is different from cytosine in hybridization behavior. In this embodiment, the pretreatment is achieved by treating with a bisulfite reagent. The modification of bisulfite DNA is carried out by using a nucleic acid extraction reagent from Boercheng (Beijing) Technology Co., Ltd.
[0222] Then, the detection system of Example 1 was added to the pre-treated DNA samples of the 100 normal volunteers to detect the Septin 9 gene. Real-time PCR was performed on the bisulfite-converted DNA.
[0223] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template and 450 nM primers (using composition 1: forward primer SEQ ID No. 1 and reverse primer SEQ ID No. 2), 225 nM probe (using composition 1: probe SEQ ID No. 3), 1 U Taq polymerase, 200 μm of each dNTP, 4.5 mM MgCl 2and 2X PCR buffer to a final volume of 50 μl. Amplify samples with pre-cycling at 94°C for 20 min, followed by 45 cycles of annealing at 62°C for 5 sec, annealing at 55.5°C for 35 sec, and denaturation at 93°C for 30 sec.
[0224] Finally, the results of 100 asymptomatic people were interpreted according to the cutoff value of the kit (≤41.0), of which 2 cases were positive for Septin9 methylation, with a false positive rate of 2%.
[0225] Table 6. Septin9 test results of 100 normal volunteers
[0226]
[0227]
[0228]
[0229]
[0230] Comparative Example
[0231] Comparative Example 1
[0232] In order to compare the primer and probe combination described in the present invention, which is significantly superior to other combinations, this comparative example will use combination 1 and combination 5 (SEQ ID Nos. 15-17) of other regions on the Septin9 gene to parallelly detect digestive tract disease samples, and compare the detection rates of the two groups of compositions for digestive tract diseases.
[0233] Composition 5:
[0234] Forward primer SEQ ID No. 15: 5'-GTAGTAGTTAGTTTAGTATTTATTTT-3'
[0235] Reverse primer SEQ ID No. 16: 5'-CCCACCAACCATCATAT-3'
[0236] Probe SEQ ID No. 17: 5′-GAACCCCGCGATCAACGCG-3′;
[0237] For 50 patients with digestive tract diseases and 50 normal volunteers (all tested by imaging or endoscopy to determine that there was no digestive tract cancer, precancerous disease or precancerous lesion), composition 1 and composition 5 were tested in parallel, and the test sample was plasma (1.2-3.5 mL), and free DNA in each sample was extracted. The DNA extraction can be carried out by any standard means in the prior art. Specifically, in this comparative example, all sample DNA was extracted by using the nucleic acid extraction reagent of Boercheng (Beijing) Technology Co., Ltd.
[0238] Then, the DNA sample is pretreated so that the 5' unmethylated cytosine base is converted into uracil, thymine or another base that is different from cytosine in hybridization behavior. In this embodiment, the pretreatment is achieved by treating with a bisulfite reagent. The modification of bisulfite DNA is carried out by using a nucleic acid extraction reagent from Boercheng (Beijing) Technology Co., Ltd.
[0239] Then, the detection system of Example 1 was added to the pretreated DNA samples of 50 people with digestive tract diseases and 50 normal volunteers, and the Septin9 gene was detected using composition 1 and composition 5 (SEQ ID Nos. 15-17), respectively, and the detection sensitivity and false positive differences of the two compositions were compared.
[0240] The PCR amplification conditions adopted in this experimental example are: real-time PCR was performed on a Life Technologies instrument (7500Fast). The PCR reaction mixture consisted of 25 μl of bisulfite-converted DNA template, 450 nM primers, 225 nM probe, 1 U Taq polymerase, 200 μM of each dNTP, 4.5 mM MgCl 2 and 2X PCR buffer to a final volume of 50 μl. Amplify samples with pre-cycling at 94°C for 20 min, followed by 45 cycles of annealing at 62°C for 5 sec, annealing at 55.5°C for 35 sec, and denaturation at 93°C for 30 sec.
[0241] Finally, according to the cutoff value of the kit (≤41.0), the results of 50 people with digestive tract diseases were interpreted (Table 7), of which 30 cases of composition 1 were positive for methylation, with a positive rate of 60.00%, and 15 cases of composition 5 (SEQ ID Nos.15-17) were positive for methylation, with a positive rate of 30.00%. For people with known digestive tract diseases, the detection rate of composition 1 is significantly better than that of compositions in other regions of the Septin9 gene, such as composition 5.
[0242] According to the cutoff value of the kit (≤41.0), the results of 50 normal volunteers were interpreted (Table 8), among which 1 case of methylation positive was found in composition 1, with a false positive rate of 2.00%, and 4 cases of methylation positive were found in composition 5 (SEQ ID Nos.15-17), with a positive rate of 8.00%. For known normal people, the false positive rate of composition 1 is significantly better than that of compositions in other regions of the Septin9 gene, such as composition 5.
[0243] Table 7. Comparison of the effects of composition 1 and compositions of other regions on the Septin9 gene in detecting digestive tract disease populations
[0244]
[0245]
[0246] Table 8. Comparison of the effects of composition 1 and compositions of other regions on the Septin9 gene in detecting normal people
[0247]
[0248]
[0249] Although the present invention has been described to a certain extent, it is obvious that appropriate changes in various conditions can be made without departing from the spirit and scope of the present invention (such as adjusting the Cutoff value for screening applications according to different uses). It can be understood that the present invention is not limited to the embodiments described, but belongs to the scope of the claims, which include equivalent replacements of each factor described.
Claims
1. Use of the composition in preparing a kit for screening the risk of esophageal cancer, precancerous lesions and precancerous diseases, characterized in that: The composition comprises a nucleic acid sequence for detecting the methylation degree in at least one target region of the Septin9 gene; Wherein, the composition is: Forward primer SEQ ID No. 4: 5'-GTCGCGTTTTTCGTCGTT-3' Reverse primer SEQ ID No. 5: 5'-CTAAACACACGACCGAAACG-3' Probe SEQ ID No. 6: 5'-CCCGCCTAACCCGCGCCC-3'.
2. Use of the composition in preparing a kit for screening gastric cancer risk, precancerous lesions and precancerous diseases, characterized in that: The composition comprises a nucleic acid sequence for detecting the methylation degree in at least one target region of the Septin9 gene; Wherein, the composition is: Forward primer SEQ ID No. 7: 5'-CGGGCGGAGTAGTTAGTGC-3' Reverse primer SEQ ID No. 8: 5'-CTCCCGAACGAATCAAATTCC-3' Probe SEQ ID No. 9: 5'-CGCACCCGCACCGACCTCC-3'.
3. Use of the composition in the preparation of a kit for screening colorectal cancer risk, precancerous lesions and precancerous diseases, characterized in that: The composition comprises a nucleic acid sequence for detecting the degree of methylation in at least one target region of the Septin9 gene; Wherein, the composition is: Forward primer SEQ ID No. 10: 5'-TTCGTTGAGAGCGTCGCG-3' Reverse primer SEQ ID No. 11: 5'-GCGCAAAATCTACGCGAATAC-3' Probe SEQ ID No. 12: 5'-CCCACGTAAACGACGCGAACACG-3'.
4. The use according to any one of claims 1 to 3, characterized in that The nucleic acid sequences are primers and probes, wherein the primers and probes have the following characteristics: they can amplify the methylated target region but cannot amplify the unmethylated target region.
5. The use according to claim 1, characterized in that: The esophageal cancer precancerous lesions and precancerous diseases include: chronic esophagitis, Barrett's esophagus, esophageal leukoplakia, esophageal diverticulum, achalasia, and reflux esophagitis.
6. The use according to claim 2, characterized in that: The gastric precancerous lesions and precancerous diseases include: atrophic gastritis, polyps, gastric ulcers, xanthomas, and intestinal metaplasia.
7. The use according to claim 3, characterized in that: The colorectal precancerous lesions and precancerous diseases include: ulcerative colitis and Crohn's disease.
